<DOC>
	<DOCNO>NCT00515554</DOCNO>
	<brief_summary>This study design test : 1. patient negative positron-emission tomography ( PET ) 2 cycle BEACOPPesc chemotherapy : whether number cycle reduce without compromise progression free survival ( PFS ) ( 2 cycle vs. 6 cycle ) 2. patient positive PET 2 cycle : whether intensify BEACOPPesc chemotherapy add Rituximab improve PFS .</brief_summary>
	<brief_title>HD18 Advanced Stages Hodgkins Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Hodgkin Lymphoma ( histologically proven ) CS ( PS ) IIB one risk factor : bulky mediastinal mass ( &gt; 1/3 maximum transverse thorax diameter ) extranodal involvement CS ( PS ) III , IV Written inform consent Leucocytes &lt; 3000/µl Platelets &lt; 100000/µl Hodgkin´s lymphoma `` composite lymphoma '' Activity index ( WHO ) &lt; grade 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hodgkin lymphoma</keyword>
	<keyword>PET</keyword>
	<keyword>advance stage</keyword>
	<keyword>Rituximab</keyword>
</DOC>